BRPI0911203A2 - peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. - Google Patents

peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.

Info

Publication number: BRPI0911203A2
Authority: BR; Brazil
Prior art keywords: peptide; derivative; peptide derivative; deficiency; patient
Prior art date: 2008-04-17

Application number

BRPI0911203A

Other languages

English (en)

Inventor

Friedrich Scheiflinger

Michael Dockal

Original Assignee

Baxter Healhcare S A

Baxter Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-17

Filing date

2009-04-16

Publication date

2016-07-05

2009-04-16 Application filed by Baxter Healhcare S A, Baxter Int filed Critical Baxter Healhcare S A

2016-07-05 Publication of BRPI0911203A2 publication Critical patent/BRPI0911203A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

BRPI0911203A 2008-04-17 2009-04-16 peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. BRPI0911203A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US932608P	2008-04-17	2008-04-17
US11305508P	2008-11-10	2008-11-10
PCT/US2009/040857 WO2009137256A1 (en)	2008-04-17	2009-04-16	Biologically active peptides

Publications (1)

Publication Number	Publication Date
BRPI0911203A2 true BRPI0911203A2 (pt)	2016-07-05

Family

ID=40887122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0911203A BRPI0911203A2 (pt)	2008-04-17	2009-04-16	peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.

Country Status (19)

Country	Link
US (6)	US8563688B2 (pt)
EP (2)	EP2279200B1 (pt)
JP (3)	JP6038452B2 (pt)
KR (2)	KR101434712B1 (pt)
CN (2)	CN102007140B (pt)
AR (1)	AR071478A1 (pt)
AU (1)	AU2009244635B2 (pt)
BR (1)	BRPI0911203A2 (pt)
CA (1)	CA2721694C (pt)
DK (2)	DK3115370T3 (pt)
ES (2)	ES2739676T3 (pt)
HK (1)	HK1223946A1 (pt)
MX (1)	MX2010011397A (pt)
NZ (1)	NZ588200A (pt)
PL (1)	PL2279200T3 (pt)
PT (1)	PT2279200T (pt)
SG (2)	SG10201809286XA (pt)
TW (2)	TWI541020B (pt)
WO (1)	WO2009137256A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI541020B (zh) *	2008-04-17	2016-07-11	巴克斯歐塔公司	生物活性胜肽
JP2013502458A (ja)	2009-08-24	2013-01-24	アムニクスオペレーティングインコーポレイテッド	凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
WO2012012444A2 (en)	2010-07-19	2012-01-26	Dolby Laboratories Licensing Corporation	Enhancement methods for sampled and multiplexed image and video data
PL2717898T3 (pl)	2011-06-10	2019-06-28	Bioverativ Therapeutics Inc.	Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
PT3564260T (pt)	2012-02-15	2023-01-18	Bioverativ Therapeutics Inc	Composições de fator viii e métodos de produção e utilização das mesmas
CA2864126A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
CA2915389C (en) *	2013-06-11	2019-06-04	Cj Cheiljedang Corporation	L-isoleucine-producing corynebacterium glutamicum strain and method of producing l-isoleucine therefrom
WO2015023894A1 (en)	2013-08-14	2015-02-19	Biogen Idec Ma Inc.	Recombinant factor viii proteins
TWI667255B (zh)	2013-08-14	2019-08-01	美商生物化學醫療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015070014A1 (en)	2013-11-08	2015-05-14	Biogen Idec Ma Inc.	Procoagulant fusion compound
US9321812B2 (en)	2014-03-28	2016-04-26	Perle Bioscience	Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) *	2014-06-03	2019-03-13	ＡｖａｎＳｔｒａｔｅ株式会社	ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) *	2014-06-12	2014-07-30	Univ Bath	Drug delivery enhancement agents
EA201890423A1 (ru)	2015-08-03	2018-07-31	Биовератив Терапьютикс Инк.	Слитые белки фактора ix, способы их получения и применения
AU2017336440B2 (en)	2016-09-28	2022-06-02	Cohbar, Inc.	Therapeutic MOTS-c related peptides
JP7748175B2 (ja)	2016-12-02	2025-10-02	バイオベラティブセラピューティクスインコーポレイテッド	キメラ凝固因子を使用して血友病性関節症を処置する方法
BR112019015569A2 (pt)	2017-01-31	2020-03-17	Bioverativ Therapeutics Inc.	Proteínas de fusão do fator ix e métodos para a sua produção e uso
CN112512555A (zh)	2018-05-18	2021-03-16	比奥维拉迪维治疗股份有限公司	治疗血友病a的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4447356A (en) *	1981-04-17	1984-05-08	Olivera Baldomero M	Conotoxins
IT1190891B (it)	1982-06-24	1988-02-24	Anic Spa	Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) *	1989-06-05	1992-03-03	Cephalon, Inc.	Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) *	1990-03-23	1995-03-22	呉羽化学工業株式会社	新規なペプチド
US5595732A (en)	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US6037452A (en)	1992-04-10	2000-03-14	Alpha Therapeutic Corporation	Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
DK0693924T4 (da)	1993-02-22	2008-08-04	Abraxis Bioscience Inc	Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US5439686A (en)	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
AU711935B2 (en) *	1994-12-30	1999-10-21	Seminis Vegetable Seeds, Inc.	Papaya ringspot virus replicase gene
US5532153A (en) *	1995-03-23	1996-07-02	New England Biolabs, Inc.	Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) *	1996-04-03	2007-10-09	Cytogen Corporation	Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en)	1999-01-04	2001-03-06	Dyax Corp.	Polypeptides for binding human factor VIII and fragments of human factor VIII
US6624289B1 (en)	1999-06-16	2003-09-23	Saint Louis University	Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en)	1999-06-16	2006-09-19	Saint Louis University	Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
JP2003503426A (ja)	1999-07-02	2003-01-28	ジェネンテック・インコーポレーテッド	ＦＶＩＩａアンタゴニスト
AT411997B (de)	1999-09-14	2004-08-26	Baxter Ag	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
AU2065801A (en) *	1999-12-06	2001-06-12	Panacea Pharmaceuticals, Llc	Passive desensitization
US20020197266A1 (en) *	2000-02-08	2002-12-26	Waldemar Debinski	Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2002256518B2 (en) *	2001-05-11	2007-07-19	Research Development Foundation	Inhibitors of receptor activator of NF-kappaB and uses thereof
FR2830865B1 (fr) *	2001-10-17	2004-10-22	Centre Nat Rech Scient	Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
US20060204503A1 (en) *	2005-01-31	2006-09-14	Biogen Idec Ma Inc.	Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
CA2632714A1 (en) *	2005-12-07	2007-06-14	Technische Universitaet Muenchen	Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP2009526754A (ja)	2006-01-04	2009-07-23	ドゥ−コープテクノロジーズリミテッド	医薬剤のインビボ取り込みを強化するための組成物および方法
TWI541020B (zh) *	2008-04-17	2016-07-11	巴克斯歐塔公司	生物活性胜肽

2009
- 2009-04-15 TW TW098112448A patent/TWI541020B/zh not_active IP Right Cessation
- 2009-04-15 AR ARP090101328A patent/AR071478A1/es active IP Right Grant
- 2009-04-15 TW TW103127214A patent/TWI573806B/zh not_active IP Right Cessation
- 2009-04-16 BR BRPI0911203A patent/BRPI0911203A2/pt not_active Application Discontinuation
- 2009-04-16 AU AU2009244635A patent/AU2009244635B2/en not_active Ceased
- 2009-04-16 CN CN200980114502.4A patent/CN102007140B/zh active Active
- 2009-04-16 US US12/425,277 patent/US8563688B2/en not_active Expired - Fee Related
- 2009-04-16 KR KR1020107025687A patent/KR101434712B1/ko not_active Expired - Fee Related
- 2009-04-16 PL PL09743243T patent/PL2279200T3/pl unknown
- 2009-04-16 SG SG10201809286XA patent/SG10201809286XA/en unknown
- 2009-04-16 NZ NZ588200A patent/NZ588200A/xx not_active IP Right Cessation
- 2009-04-16 EP EP09743243.9A patent/EP2279200B1/en active Active
- 2009-04-16 EP EP16172509.8A patent/EP3115370B1/en active Active
- 2009-04-16 ES ES16172509T patent/ES2739676T3/es active Active
- 2009-04-16 DK DK16172509.8T patent/DK3115370T3/da active
- 2009-04-16 SG SG10201608071YA patent/SG10201608071YA/en unknown
- 2009-04-16 PT PT97432439T patent/PT2279200T/pt unknown
- 2009-04-16 JP JP2011505212A patent/JP6038452B2/ja not_active Expired - Fee Related
- 2009-04-16 CA CA2721694A patent/CA2721694C/en active Active
- 2009-04-16 ES ES09743243.9T patent/ES2594706T3/es active Active
- 2009-04-16 CN CN201610040575.5A patent/CN105524163A/zh active Pending
- 2009-04-16 KR KR1020137024826A patent/KR101606248B1/ko not_active Expired - Fee Related
- 2009-04-16 MX MX2010011397A patent/MX2010011397A/es active IP Right Grant
- 2009-04-16 WO PCT/US2009/040857 patent/WO2009137256A1/en not_active Ceased
- 2009-04-16 DK DK09743243.9T patent/DK2279200T3/en active
2011
- 2011-09-21 US US13/238,751 patent/US8822638B2/en active Active
2013
- 2013-12-20 JP JP2013263345A patent/JP5977223B2/ja not_active Expired - Fee Related
2014
- 2014-07-24 US US14/340,231 patent/US9206234B2/en active Active
2015
- 2015-11-13 US US14/941,163 patent/US9598464B2/en not_active Expired - Fee Related
2016
- 2016-07-21 JP JP2016143368A patent/JP2017019797A/ja active Pending
- 2016-10-19 HK HK16112064.8A patent/HK1223946A1/zh unknown
2017
- 2017-02-27 US US15/443,949 patent/US10287319B2/en active Active
2019
- 2019-03-20 US US16/359,763 patent/US10822376B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20120077749A1 (en)	2012-03-29
NZ588200A (en)	2012-11-30
TW200944226A (en)	2009-11-01
US20190225648A1 (en)	2019-07-25
PL2279200T3 (pl)	2017-08-31
AU2009244635A1 (en)	2009-11-12
US8563688B2 (en)	2013-10-22
US10287319B2 (en)	2019-05-14
DK2279200T3 (en)	2016-08-22
US20150038676A1 (en)	2015-02-05
ES2594706T3 (es)	2016-12-22
JP2014074052A (ja)	2014-04-24
CA2721694C (en)	2018-11-06
US20160060295A1 (en)	2016-03-03
US9598464B2 (en)	2017-03-21
CN105524163A (zh)	2016-04-27
JP5977223B2 (ja)	2016-08-24
KR20130112959A (ko)	2013-10-14
EP2279200A1 (en)	2011-02-02
TW201443085A (zh)	2014-11-16
TWI541020B (zh)	2016-07-11
ES2739676T3 (es)	2020-02-03
CN102007140A (zh)	2011-04-06
SG10201809286XA (en)	2018-11-29
HK1223946A1 (zh)	2017-08-11
US20100022445A1 (en)	2010-01-28
JP2011518179A (ja)	2011-06-23
TWI573806B (zh)	2017-03-11
JP2017019797A (ja)	2017-01-26
MX2010011397A (es)	2010-11-12
KR101606248B1 (ko)	2016-03-24
KR101434712B1 (ko)	2014-10-01
CN102007140B (zh)	2016-02-24
AR071478A1 (es)	2010-06-23
DK3115370T3 (da)	2019-07-29
US8822638B2 (en)	2014-09-02
US10822376B2 (en)	2020-11-03
HK1154255A1 (zh)	2012-04-13
CA2721694A1 (en)	2009-11-12
EP3115370A1 (en)	2017-01-11
SG10201608071YA (en)	2016-11-29
US9206234B2 (en)	2015-12-08
WO2009137256A1 (en)	2009-11-12
EP2279200B1 (en)	2016-07-13
KR20110005873A (ko)	2011-01-19
AU2009244635B2 (en)	2012-04-19
PT2279200T (pt)	2016-10-12
US20170174724A1 (en)	2017-06-22
EP3115370B1 (en)	2019-06-26
JP6038452B2 (ja)	2016-12-07

Similar Documents

Publication	Publication Date	Title
BRPI0911203A2 (pt)	2016-07-05	peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0916235A2 (pt)	2018-03-13	composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
BRPI0717219A2 (pt)	2015-05-26	"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
DOP2010000304A (es)	2011-10-15	Composiciones y metodos de preparacion y uso de las mismas
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BR112012003462A2 (pt)	2016-02-23	"composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0816330A2 (pt)	2015-04-14	Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
BRPI0816097A2 (pt)	2016-11-01	composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0816320A2 (pt)	2015-03-24	Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0816255A2 (pt)	2015-03-17	Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável

Legal Events

Date	Code	Title	Description
2017-05-23	B25A	Requested transfer of rights approved	Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-09-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-10-05	B25A	Requested transfer of rights approved	Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)
2022-03-29	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2022-09-06	B09B	Patent application refused [chapter 9.2 patent gazette]
2022-11-16	B12B	Appeal against refusal [chapter 12.2 patent gazette]